 abc13.com | Women With Previously Treated Advanced Breast Cancer Benefit From Addition Of ... Medical News Today The mammalian target of rapamycin (mTOR) inhibitor everolimus given with the aromatase inhibitor exemestane markedly boosts progression-free survival (PFS) in post-menopausal women with advanced breast cancer compared with hormonal therapy alone, ... Everolimus plus AI extends survival Study: Pill can help stop spread of cancer |
